Acquisition Announced
Eli Lilly and Company acquisition of Ventyx Biosciences
US$1.2bn equity value
Announced 7 Jan 2026 · NASDAQ: VTYX · US$14.00 cash per share · 62% premium
Advisers
- Target
- Ventyx Biosciences
- Acquirer
- Eli Lilly and Company
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Drug Development, Pharma
In the league tables
Similar deals
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
- Hansoh Pharmaceutical Group Co. stake in Avere Therapeutics Jul 2026 · Biotech
- Adial Pharmaceuticals acquisition of Azora Therapeutics Jun 2026 · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Eli Lilly acquisition of Curevo Vaccine May 2026 · US$1.5bn · Biotech
Sources
- 2026 Moelis & Company: Sale to Eli Lilly moelis.com
- 7 Jan 2026 Press release (EX-99.1, exhibit), Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases sec.gov
- 7 Jan 2026 Press release (PR Newswire), Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases prnewswire.com
- 2 Feb 2026 Definitive merger proxy statement (DEFM14A), Ventyx Biosciences, Inc. sec.gov


